Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 165, Issue 3, pp 386–389 | Cite as

Directed Change in TNFα Specificity to Create DR5 Antagonists

  • V. M. Ukrainskaya
  • T. V. Bobik
  • A. Argentova-Stevens
  • E. A. Slutskaya
  • R. S. Kalinin
  • A. G. Gabibov
  • A. V. Stepanov
Article
  • 1 Downloads

Death receptor 5 (DR5) is a promising target for antitumor therapy due to its high expression on different tumor cells. Resistance of various tumor cells against TRAIL, a natural ligand for the death receptors, reduces its therapeutic potential and prompts the search for novel agonists at these receptors. Previous screening across the combinatorial peptide library yielded a peptide sequence KVVLTHR that specifically binds DR5. Incorporation of this sequence into TNFα resulted in binding DR5 with mutant protein TNFα-mut and appearance of cytotoxicity against lymphoma cells.

Key Words

death receptor 5 TRAIL TNF apoptosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp. Biol. Med. (Maywood). 2015;240(6):760-773.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biol. 2016;37(7):8471-8486.CrossRefGoogle Scholar
  3. 3.
    Naoum GE, Buchsbaum DJ, Tawadros F, Farooqi A, Arafat WO. Journey of TRAIL from bench to bedside and its potential role in immuno-oncology. Oncol. Rev. 2017;11(1):332. doi:  https://doi.org/10.4081/oncol.2017.332. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H. The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu. Rev. Immunol. 2007;25:561-586.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tummers B, Green DR. Caspase-8: regulating life and death. Immunol. Rev. 2017;277(1):76-89.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ukrainskaya VM, Stepanov AV, Belogurov AA Jr, Gabibov AG. Combinatorial screening of peptides, specific ligands of death receptor DR5. Bull. Exp. Biol. Med. 2017;163(3):381-384.CrossRefPubMedGoogle Scholar
  7. 7.
    Van Ostade X, Tavernier J, Prangé T, Fiers W. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 1991;10(4):827-836.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002;7(5):449-459.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27(48):6207-6215.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol. Sin. 2008;29(11):1275-1288.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • V. M. Ukrainskaya
    • 1
  • T. V. Bobik
    • 1
  • A. Argentova-Stevens
    • 1
  • E. A. Slutskaya
    • 1
  • R. S. Kalinin
    • 1
  • A. G. Gabibov
    • 1
  • A. V. Stepanov
    • 1
  1. 1.Laboratory of Biocatalysis, M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia

Personalised recommendations